Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392703 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
NCT01392703: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT01392703 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 141 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (135% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01392703, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the blood levels of dasatinib in healthy participants who received tablet formulation with those of healthy participants who received liquid and tablet-dispersed formulations of the drug.
Primary Outcome
Single-dose pharmacokinetic parameters, including Cmax, were derived using noncompartmental methods from plasma dasatinib concentration-time data.
Interventions
- DRUG Dasatinib as tablets
- DRUG Dasatinib as liquid
- DRUG Dasatinib as dispersed tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
What the finished NCT01392703 record still lists
NCT01392703 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (135% higher).
The record links to 0 conditions, and to 3 interventions - of which Dasatinib as tablets is the first listed.
NCT01392703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01392703 about?
NCT01392703 is a clinical study titled "Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations". The purpose of the study is to compare the blood levels of dasatinib in healthy participants who received tablet formulation with those of healthy participants who received liquid and tablet-dispersed formulations of the drug.
What is the current status of trial NCT01392703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2011-07. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01392703?
The interventions under investigation include: Dasatinib as tablets (DRUG), Dasatinib as liquid (DRUG), Dasatinib as dispersed tablets (DRUG).
Who is sponsoring clinical trial NCT01392703?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01392703's enrollment target sits among peer trials
141 401st of 2000 higher than 1,599 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia